February 10, 2026

TempraMed Technologies Ltd.
ISIN: CA88024B1022
TempraMed Partners with Super-Pharm, Israel’s Leading Pharmacy Chain to Commence a National Product Roll Out Strategy
Super-Pharm operates nationwide, serving millions of consumers annually Vancouver, BC - February 10, 2026 - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how...
Read more >>
TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadership. Vancouver, BC – December 10, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr....
Read more >
TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, BC – December 8, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI...
Read more >
TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
Vancouver, BC – December 5, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a distribution partnership with Salomo Executive, a leading healthcare logistics and consultancy company...
Read more >
TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market
- Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products to gain traction - Turkey is one of the highest-prevalence diabetes countries in Europe due to obesity rates, diet, urbanization, and low screening compliance - One of many distribution...
Read more >
TempraMed Signs Exclusive Distribution Agreement with Leading Consumer Health Distributor in Israel
- Leading distributor of global companies including GSK/Haleon, Cargill, Reynolds, Paskesz - Guri distributes reputable brands including Sensodyne, Aquafresh, Parodontax, Truvia, Diamond and more- Strategic agreement supports TempraMed’s global shift from online B2C to major pharmacy networks and B2B medical payors- Distribution to over 2,500 outlets including pharmacy chains, supermarkets,...
Read more >